A phase II/III study of CB 813d as a potential treatment of bleeding in hemophilia patients with inhibitors

Trial Profile

A phase II/III study of CB 813d as a potential treatment of bleeding in hemophilia patients with inhibitors

Planning
Phase of Trial: Phase II/III

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Marzeptacog alfa (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Registrational; Therapeutic Use
  • Sponsors Catalyst Biosciences
  • Most Recent Events

    • 02 Nov 2017 According to a Catalyst Biosciences media release, interim results from this trial are expected in first half of 2018.
    • 26 Jun 2017 Phase 2 part of this trial is expected to commence by the end of 2017, according to a Catalyst Biosciences media release.
    • 30 Mar 2017 According to a Catalyst Biosciences media release, company has selected INC Research (CRO) to conduct this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top